<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02031146</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00001718</org_study_id>
    <secondary_id>R01NS082120</secondary_id>
    <nct_id>NCT02031146</nct_id>
  </id_info>
  <brief_title>Lumbar Puncture and Syphilis Outcome</brief_title>
  <official_title>Lumbar Puncture and Syphilis Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treponema pallidum, the bacterium that causes syphilis, invades the central nervous system in&#xD;
      about 40% of patients with syphilis. This happens early after infection. Patients with&#xD;
      neuroinvasion are at risk of developing serious neurological complications, including vision&#xD;
      or hearing loss, stroke and dementia. Because neuroinvasion can happen without symptoms, the&#xD;
      only way to identify it is by performing a lumbar puncture (LP) to examine cerebrospinal&#xD;
      fluid (CSF).The overall hypothesis to be tested in this study is that a strategy of immediate&#xD;
      LP, followed by therapy based on CSF evaluation, results in better serological and functional&#xD;
      outcomes in patients with syphilis who are at high risk for neuroinvasion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">December 2020</completion_date>
  <primary_completion_date type="Actual">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Appropriate Decline in Serum Rapid Plasma Reagin Test (RPR) Titer</measure>
    <time_frame>6-12 months +/- 4 weeks</time_frame>
    <description>Decline in serum RPR titer by four-fold or to nonreactive at 6 months (+/- 4 weeks) in early syphilis or at 12 months (+/- 4 weeks) in late syphilis. This is the definition of treatment success according to the US Centers for Disease Control and Prevention guidelines.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Improvement in Performance on CogState Battery.</measure>
    <time_frame>6-12 months +/- 4 weeks</time_frame>
    <description>Assessment of cognitive impairment was based on age adjusted normative data from CogState and was categorized as none (all test scores &gt; -1 standard deviation [SD] of normative data), mild impairment (two test scores &lt; -1 SD, or one test score &lt; -2 SD), moderate impairment (two test scores &lt; -2 SD) or severe impairment (three test scores &lt; -2 SD). Participants were categorized as improved if they had any impairment at study entry and improved by at least one category.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">231</enrollment>
  <condition>Syphilis</condition>
  <arm_group>
    <arm_group_label>LP</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants undergo lumbar puncture for CSF evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No LP</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants do not undergo lumbar puncture and CSF is not examined.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lumbar puncture</intervention_name>
    <arm_group_label>LP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females age 18 years or older&#xD;
&#xD;
          2. Current syphilis&#xD;
&#xD;
          3. Primary language is English or English is a second language but patient self-describes&#xD;
             as fluent in English&#xD;
&#xD;
          4. Able to provide informed consent&#xD;
&#xD;
          5. If treated with benzathine penicillin G (BPG), it must have occurred less than 14 days&#xD;
             before the entry visit (before the first visit if there is more than one entry visit)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Provider plans neurosyphilis (NS) treatment regardless of whether the patient has an&#xD;
             lumbar puncture (LP)&#xD;
&#xD;
          2. Receipt of antibiotic treatment that would be effective for NS (for example, IV or&#xD;
             intramuscular (IM) beta-lactam antibiotics [other than BPG]) within one month before&#xD;
             study entry; single dose of IM ceftriaxone in the last month is not exclusionary&#xD;
&#xD;
          3. Allergy to penicillin or lidocaine&#xD;
&#xD;
          4. Contraindication to LP, including untreatable coagulation disorder, use of&#xD;
             anticoagulants that cannot be temporarily discontinued, thrombocytopenia, focal&#xD;
             neurological examination&#xD;
&#xD;
          5. Other known cause of central nervous system (CNS) infection in the last year,&#xD;
             including that due to bacterial, fungal, protozoal or viral agents, such as&#xD;
             tuberculosis, Cryptococcus, toxoplasmosis or herpes zoster that could confound&#xD;
             interpretation of CSF results&#xD;
&#xD;
          6. Unlikely to be able to comply with study requirements or complete the study, for&#xD;
             example, planning to leave the area &lt; 6 months after enrollment&#xD;
&#xD;
          7. Subjects will not be allowed to re-enroll in this study with a new episode of syphilis&#xD;
&#xD;
        Individuals who are unwilling to be randomized can choose LP or no LP. Eligibility criteria&#xD;
        for these individuals are:&#xD;
&#xD;
          1. 18 years of age or older&#xD;
&#xD;
          2. Current syphilis infection&#xD;
&#xD;
          3. Primary language is English or fluent in English&#xD;
&#xD;
          4. No contraindications to LP&#xD;
&#xD;
          5. Have not received antibiotics within one month that would treat neurosyphilis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina M Marra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 6, 2014</study_first_submitted>
  <study_first_submitted_qc>January 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2014</study_first_posted>
  <results_first_submitted>December 16, 2020</results_first_submitted>
  <results_first_submitted_qc>May 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 25, 2021</results_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Christina Marra</investigator_full_name>
    <investigator_title>Professor, Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syphilis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 16, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT02031146/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The protocol section asks how many participants were enrolled. 219 unique participants were enrolled, but 12 had two enrollments. Thus there are 231 enrollment visits.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Randomized, Lumbar Puncture (LP)</title>
          <description>Randomized to lumbar puncture (LP) arm</description>
        </group>
        <group group_id="P2">
          <title>Reenrolled, Randomized, LP</title>
          <description>Randomised after a second enrollment, underwent LP</description>
        </group>
        <group group_id="P3">
          <title>Randomized, no LP</title>
          <description>Randomized and did not undergo LP. Includes one person for whom LP was unsuccessful.</description>
        </group>
        <group group_id="P4">
          <title>Not Randomized, LP</title>
          <description>Not randomized and underwent LP.</description>
        </group>
        <group group_id="P5">
          <title>Not Randomized, no LP</title>
          <description>Not randomized and did not undergo LP.</description>
        </group>
        <group group_id="P6">
          <title>Reenrolled, Not Randomized, no LP</title>
          <description>Not randomized during another episode of syphilis. Did not undergo LP.</description>
        </group>
        <group group_id="P7">
          <title>Reenrolled, Not Randomized, LP</title>
          <description>Not randomized with a new episode of syphilis, underwent LP</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="148"/>
                <participants group_id="P5" count="42"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Considered in Analysis</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="48"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="48"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="100"/>
                <participants group_id="P5" count="26"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not meet criteria for inclusion in data analysis</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="100"/>
                <participants group_id="P5" count="26"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lumbar Puncture Group</title>
          <description>Underwent lumbar puncture</description>
        </group>
        <group group_id="B2">
          <title>No Lumbar Puncture Group</title>
          <description>Did not undergo lumbar puncture</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" lower_limit="29" upper_limit="45"/>
                    <measurement group_id="B2" value="34" lower_limit="27" upper_limit="40"/>
                    <measurement group_id="B3" value="35" lower_limit="28" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>number in each category of race</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Rapid Plasma Reagin test (RPR) titer</title>
          <description>Titers are expressed as 2-fold dilutions:&#xD;
1:1 1:2 1:4 1:8 and so on.</description>
          <units>titer</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128" lower_limit="32" upper_limit="256"/>
                    <measurement group_id="B2" value="128" lower_limit="64" upper_limit="256"/>
                    <measurement group_id="B3" value="128" lower_limit="64" upper_limit="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Impaired on CogState Battery</title>
          <description>The CogState is a computerized battery of neuropsychological tests. Assessment of cognitive impairment was based on age adjusted normative data, categorized as none (all test scores &gt; -1 standard deviation [SD] of normative data), mild impairment (two test scores &lt; -1 SD, or one test score &lt; -2 SD), moderate impairment (two test scores &lt; -2 SD) or severe impairment (three test scores &lt; -2 SD).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Appropriate Decline in Serum Rapid Plasma Reagin Test (RPR) Titer</title>
        <description>Decline in serum RPR titer by four-fold or to nonreactive at 6 months (+/- 4 weeks) in early syphilis or at 12 months (+/- 4 weeks) in late syphilis. This is the definition of treatment success according to the US Centers for Disease Control and Prevention guidelines.</description>
        <time_frame>6-12 months +/- 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lumbar Puncture (LP), Treatment Based on Cerebrospinal Fluid (CSF ) Results</title>
            <description>Underwent lumbar puncture and treatment based on the results of cerebrospinal fluid findings. Specifically, those with abnormal CSF were treated for neurosyphilis and those without CSF abnormalities were treated for uncomplicated syphilis. The number of participants with late syphilis was too small to allow for separate analysis of early and late stages.</description>
          </group>
          <group group_id="O2">
            <title>No Lumbar Puncture Group</title>
            <description>Did not undergo lumbar puncture. All were treated for uncomplicated syphilis. The number of participants with late syphilis was too small to allow for separate analysis of early and late stages.</description>
          </group>
        </group_list>
        <measure>
          <title>Appropriate Decline in Serum Rapid Plasma Reagin Test (RPR) Titer</title>
          <description>Decline in serum RPR titer by four-fold or to nonreactive at 6 months (+/- 4 weeks) in early syphilis or at 12 months (+/- 4 weeks) in late syphilis. This is the definition of treatment success according to the US Centers for Disease Control and Prevention guidelines.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>Two sample test of proportion in Stata</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Improvement in Performance on CogState Battery.</title>
        <description>Assessment of cognitive impairment was based on age adjusted normative data from CogState and was categorized as none (all test scores &gt; -1 standard deviation [SD] of normative data), mild impairment (two test scores &lt; -1 SD, or one test score &lt; -2 SD), moderate impairment (two test scores &lt; -2 SD) or severe impairment (three test scores &lt; -2 SD). Participants were categorized as improved if they had any impairment at study entry and improved by at least one category.</description>
        <time_frame>6-12 months +/- 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lumbar Puncture (LP), Treatment Based on Cerebrospinal Fluid (CSF ) Results</title>
            <description>Underwent lumbar puncture and treatment based on the results of cerebrospinal fluid findings. Specifically, those with abnormal CSF were treated for neurosyphilis and those without CSF abnormalities were treated for uncomplicated syphilis.</description>
          </group>
          <group group_id="O2">
            <title>No Lumbar Puncture Group</title>
            <description>Did not undergo lumbar puncture. All were treated for uncomplicated syphilis.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Improvement in Performance on CogState Battery.</title>
          <description>Assessment of cognitive impairment was based on age adjusted normative data from CogState and was categorized as none (all test scores &gt; -1 standard deviation [SD] of normative data), mild impairment (two test scores &lt; -1 SD, or one test score &lt; -2 SD), moderate impairment (two test scores &lt; -2 SD) or severe impairment (three test scores &lt; -2 SD). Participants were categorized as improved if they had any impairment at study entry and improved by at least one category.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" lower_limit="7.5" upper_limit="15.2"/>
                    <measurement group_id="O2" value="12.2" lower_limit="3.0" upper_limit="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.69</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Time to Decline in Performance on the CogState Battery</title>
        <description>Participants were categorized as declined if they were not severely impaired at entry and declined by at least one category. The impairment categories are: none (all test scores &gt; -1 standard deviation [SD] of normative data), mild impairment (two test scores &lt; -1 SD, or one test score &lt; -2 SD), moderate impairment (two test scores &lt; -2 SD) or severe impairment (three test scores &lt; -2 SD).</description>
        <time_frame>6-12 months +/- 4 weeks</time_frame>
        <population>Time to decline in performance on the CogState battery by log rank test.</population>
        <group_list>
          <group group_id="O1">
            <title>Underwent Lumbar Puncture (LP), Abnormal Cerebrospinal Fluid (CSF), Treated for Neurosyphilis (NS)</title>
            <description>Cerebrospinal fluid (CSF) white cells above 5/ul, supporting the diagnosis of neurosyphilis, and treated for neurosyphilis with antibiotics.</description>
          </group>
          <group group_id="O2">
            <title>No LP or Normal CSF and Not Treated for Neurosyphilis</title>
            <description>Combination of participants who didn't undergo LP and those who did but had CSF white cells less than or equal to 5/ul and nonreactive cerebrospinal fluid Venereal Disease Research Laboratory (CSF-VDRL) test, and weren't treated for neurosyphilis. In other words, those who didn't undergo LP and those who did have an LP but didn't meet diagnostic criteria for neurosyphilis.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Decline in Performance on the CogState Battery</title>
          <description>Participants were categorized as declined if they were not severely impaired at entry and declined by at least one category. The impairment categories are: none (all test scores &gt; -1 standard deviation [SD] of normative data), mild impairment (two test scores &lt; -1 SD, or one test score &lt; -2 SD), moderate impairment (two test scores &lt; -2 SD) or severe impairment (three test scores &lt; -2 SD).</description>
          <population>Time to decline in performance on the CogState battery by log rank test.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Less than 50% of individuals worsened, so no median time can be reported.</measurement>
                    <measurement group_id="O2" value="12.3" lower_limit="4.1" upper_limit="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>One year</time_frame>
      <desc>No difference</desc>
      <group_list>
        <group group_id="E1">
          <title>Underwent Lumbar Puncture</title>
          <description>Participants who underwent lumbar puncture.</description>
        </group>
        <group group_id="E2">
          <title>Did Not Undergo Lumbar Puncture</title>
          <description>Participants who did not undergo lumbar puncture.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Inclusion of a non-randomized group introduces risk of bias; however, the groups were comparable with regard to neurosyphilis risk factors.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Christina Marra, MD</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-744-3251</phone>
      <email>cmarra@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

